IXALTIS IXALTIS
  • Home
  • Company
    • About us
    • Genito-urinary diseases
  • Governance
    • Board of Directors
    • Scientific Advisory Board
    • Management
  • R&D
    • Pipeline
    • Litoxetine (IXA-001)
    • IXA-002 & IXA-003
    • MAGenTA
  • Press
  • Contact
Bref, June 2016
juin 08, 201629 août 2017

Bref, June 2016

In Press
Previous Link
Capital Finance, June 2016
Next Link
Eco des Savoie, June 2016

Articles récents

  • Press Release, Ixaltis – Completion of Scientific Advice and End-of-Phase 2 interactions with EMA and FDA respectively, February 2020
  • Press Release, Ixaltis – Positive Results from phase 2 studies for Litoxetine, October 2019
  • Press Release, Ixaltis-Successful Completion of phase 2 for Litoxetine, May 2019
  • Press Release, Ixaltis-Completion of recruitment in EU/Canada, July 2018
  • Press Release, Ixaltis-US Study starts, April 2018

Archives

IXALTIS

Archamps Technopôle, Acti'Tech 6, 60 avenue Marie CurieArchampsFrance74160
+33 (0)4 57 26 00 76

Find us

Website

Legal Mentions

IXALTIS © 2017 / All Rights Reserved